BACKGROUND: Unwanted weight gain is often reported in people living with HIV (PWH) who start on or switch to integrase strand transfer inhibitors (INSTI). Mechanisms are incompletely understood. An unintended off-target of INSTI might be the gut microbiota. METHODS: We explored the fecal microbiota of treated aviremic PWH (nâ=â70) who switched from efavirenz (EFV)- to a bictegravir (BIC)-based regimen. 16S rRNA sequencing, and enzyme-linked immunosorbent assays were used to characterize the fecal microbiota and quantify markers of HIV disease progression. A cohort of high-risk HIV-negative individuals (nâ=â18) was included to address differential effects of antiretroviral therapy (ART) on the fecal microbiota. RESULTS: This real-life cohort was predominantly male (nâ=â63) and mostly men who have sex with men (nâ=â40). All PWH were on the same antiretroviral regimen for at least 1 year; the mean time on ART was 10.83 ± 5.530 years and all had undetectable plasma viral loads (<â40 HIV-1 RNA copies/mL). PWH gained a median weight of 3.375 kg and the mean percent weight change relative to baseline was 4.32%. Seven (10%) PWH gained significant weight (>â10% relative to baseline). Switching to a BIC-based regimen had contrasting effects. PWH on BIC/FTC/TAF showed decreased microbial translocation (soluble CD14, sCD14), decreased enterocyte damage (intestinal fatty-acid binding protein, I-FABP), and increased alpha diversity (richness and shannon); all indicative of a better restoration of the gut mucosa and microbiota. Conversely, increases in sCD163, monocyte chemoattractant protein 1 (MCP-1) and decreases in adiponectin, markers linked to cardiovascular disease, insulin resistance and adiposity, were unfavorable. CONCLUSION: Our data suggest that INSTI have a less detrimental effect on the gut microbiota compared to EFV-based regimen. The link between weight gain on INSTI and the gut microbiota was not readily apparent.
Differential effects of switching to integrase strand transfer inhibitors on the gut microbiota and markers of HIV disease progression.
改用整合酶链转移抑制剂对肠道菌群和 HIV 疾病进展标志物的不同影响
阅读:16
作者:Pinto-Cardoso Sandra M, Aguilar-Vargas Adriana, López-Filloy Mariana, Chávez-Torres Monserrat, Murakami-Osawara Akio, Briceño Olivia, Romero-Mora Karla, RodrÃguez-Moguel Nadia, Salgado Montes de Oca Gonzalo, Ãvila-RÃos Santiago
| 期刊: | BMC Microbiology | 影响因子: | 4.200 |
| 时间: | 2025 | 起止号: | 2025 Sep 1; 25(1):569 |
| doi: | 10.1186/s12866-025-04313-9 | 研究方向: | 其它 |
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
